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In patients with hypertrophic cardiomyopathy (HCM), impaired left ventricular (LV) relaxation and diastolic
filling have been reported. Therefore, we determined L V diastolic stiffness in nine patients with HCM before
and 10 to 15 min after 0-15 mg/kg propranolol i. v. (group 1) and in six patients with HCM before and 10 to
15 min after 0-1 mg/kg verapamil i.v. (group 2). Simultaneous LV cineangiography and high-fidelity pressure
measurements were performed in group 1 and simultaneous M-mode echocardiography and high-fidelity
pressure measurements in group 2. Passive LV chamber stiffness was determined in group 1 from the diastolic
pressure-volume data using an exponential three-parameter model: P=aePy +C, where P=pressure,
a = intercept, ft = constant of chamber stiffness, V= volume and C = baseline pressure. Passive L V myocardial
stiffness was estimated in group 2 from the diastolic stress-strain data using a viscoelastic model:
o = a'(eP't- \) + r\k, where o = meridional wall stress, a = intercept, P' = constant of myocardial stiffness,
e = midwall strain, r\ = constant ofmyocardial viscosity and £ =strain rate. LV relaxation was assessed from the
time constant of LV pressure decay (T) by plotting LV pressure versus negative dP/dt. LV diastolic filling was
evaluated from peak and mean L V filling rate in group 1 and from peak and mean midwall lengthening rate in
group 2.
L V chamber and myocardial stiffness, respectively, remained unchanged before and after administration of
propranolol (p = 0-054 and 0-047) and verapamil (ft' = 14-8 and 12-6); however, the time constant of LV
pressure decay T increased significantly in group 1 from 45 to 66 ms (P<0-05) and decreased significantly in
group 2 from 53 to 43 ms (P<0-05). Parallel to the changes in LV isovolumic relaxation, mean LV diastolic
filling rate decreased significantly in group 1 from 257 to 196 ml m~2 s~' (P<0-025) and mean LV midwall
lengthening rate increased significantly in group 2 from 2-37 to 4-31 cm /sec (P<0-05).
It is concluded that L V diastolic stiffness remains unchanged in patients with HCM after propranolol and
verapamil. LV relaxation and mean diastolic filling, however, are impaired in patients with HCM following
propranolol but are improved after verapamil. Thus, the beneficial effect of verapamil on diastolic mechanics
is related to improved relaxation and diastolic filling rather than to changes in LV diastolic stiffness.
Introduction a systolic outflow gradient. A favourable effect of 0
blocking agents on the systolic outflow tract gradient
Abnormal left ventricular diastolic function and is well established, whereas it remains controversial
impaired left ventricular filling dynamics""41 have whether the passive diastolic chamber stiffness is
been reported in patients with hypertrophic cardio- altered by the administration of B blocking
myopathy. The increased resistance to ventricular agents'56'. Kaltenbach and coworkers17' reported a
filling (diastolic compliance failure) is probably salutary response to verapamil in patients with
responsible for clinical symptoms such as dyspnea hypertrophic cardiomyopathy, and recently Lorell
and lung congestion, and is considered to be the and coworkers(8) showed a favourable effect of
major problem in patients with hypertrophic cardio- nifedipine on abnormal left ventricular relaxation
myopathy, irrespective of the presence or absence of and diastolic filling rates in patients with
hypertrophic cardiomyopathy.
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Figure 1 Left ventricular biplane cineangiograms in
a patient with hypertrophic cardiomyopathy before
(upper panel) and after (lower panel) intravenous
administration of propranolol. Note the slight
increase in left ventricular chamber size following
propranolol ed: end-diastole; es: end-systole; RAO,
LAO: right, left anterior oblique projection.
left ventricular diastolic mechanics in 15 patients
with hypertrophic cardiomyopathy, and to determine
whether or not relaxation and passive diastolic
chamber and myocardial stiffness can be influenced
by the administration of these drugs.
Patients and methods
Fifteen patients with the typical clinical,
haemodynamic, echocardiographic and angiographic
findings of hypertrophic cardiomyopathy were
included in the present study. All patients were in
sinus rhythm and all medications were discontinued
24 to 48 h prior to catheterization.
Nine patients (group 1) were studied at rest and 10
to 15 min after intravenous administration of 0-15
mg/kg propranolol, and six patients (group 2) were
studied 10 to 15 min after intravenous administration
ofO-1 mg/kg verapamil. Three patients of group 1 had
undergone previous septal myectomy, and two of
them had left bundle branch block following surgery
(QRS duration 0-14 s in both). In all other patients
QRS duration did not exceed 0-11 s. The mean age
was similar in both groups (43 and 47 years,
respectively). The nine patients of group 1 have been
published previously"1. Four patients of group 1 had
no pressure gradient at rest but developed one after
postextrasystolic potentiation or Valsalva
manoeuvre; in group 2, three patients demonstrated
only small systolic pressure gradients (<10 mmHg) at
rest.
Standard haemodynamic measurements were per-
formed in both groups at rest and 10 to 15 min after
the administration of propranolol or verapamil. Left
ventricular pressure was measured with a trans-
septally introduced Millar micromanometer; simul-
taneous aortic pressure was determined by a fluid-
filled catheter. Biplane cineangiography was
performed at 50 frames/s in the right (RAO) and left
anterior oblique (LAO) projection with simultaneous
recordings of left ventricular high-fidelity pressure,
its first derivative (dP/dt) and a peripheral lead of
the standard electrocardiogram*5'. In group 1
patients a second biplane cineangiogram was carried
out 10 to 15 min following intravenous adminis-
tration of propranolol (Fig. 1).
Simultaneous M-mode echocardiography and
high-fidelity pressure measurements (Fig. 2) were
performed in group 2 patients at rest and 10 to 15
min after intravenous administration of 0 - l mg/kg
verapamil. Left ventricular high-fidelity pressure,
conventional aortic pressure, dP/di, the
phonocardiogram and a peripheral lead of the
standard electrocardiogram were recorded on an
oscillograph (Electronics for Medicine VR-12) at a
paper speed of 100 mm/s1".
Data analysis
Frame by frame analysis was performed for deter-
mination of left ventricular biplane volume in group
1 according to the area-length method*5'. Matching
of the individual cineframe with the left ventricular
high-fidelity pressure was carried out by a numerical
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Figure 2 Left ventricular simultaneous echo-pressure
measurements in a patient with hypertrophic cardio-
myopathy before (upper panel) and after (lower panel)
intravenous administration of 8 mg verapamil. Note that
there is a small systolic pressure gradient between the left
ventricular (LVP) and the aortic pressure (AoP) tracing after
verapamil. The heavy echo in the mid-portion of the left
ventricular cavity stems from the Millar tip manometer. IVS,
interventricular septum; PW, posterior wall; dP/dt, first
derivative of LVP; ECG, electrocardiogram; PCG,
phonocardiogram; D, diameter; P, pressure.
code which appeared on both the cinefilm and the
pressure tracing'5*.
The M-mode echocardiograms and high-fidelity
pressure tracings (Fig. 2) in group 2 were digitized by
a computer-assisted system, and instantaneous left
ventricular internal and midwall diameter, meri-
dional wall stress and midwall lengthening rate were
calculated at time intervals of 5 to 10 ms"1.
For the assessment of left ventricular chamber
stiffness, the pressure—volume data in group 1 were
fitted to an exponential pressure-volume
relationship using a three-parameter model:
where P= pressure (mmHg), a = intercept (mmHg),
P = constant of left ventricular chamber stiffness,
V= volume (ml/m2) and C= baseline pressure
(mmHg). The mathematical analysis was performed
by an iteration procedure1101 using a non-linear curve-
fitting program"" to determine the three constants a,
P and C.
For the assessment of left ventricular myocardial
stiffness the stress-strain data in group 2 were fitted
to an exponential viscoelastic stress-strain model
incorporating an elastic and a viscous term"01:
where o = meridional wall stress (g(cm2),
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a'= intercept (g/cm2), p = constant of left
ventricular myocardial stiffness, E = midwall strain,
r} = constant of left ventricular myocardial viscosity
(g s cm"2) and e = strain rate (s~'). Left ventricular
midwall strain (e) was normalized to a reference
midwall circumference (0 at a common wall stress of
1 g/cm2 calculated from the viscoelastic
stress-circumference relationship"01. This midwall
circumference at 1 g/cm2 (/,) was used for the
determination of normalized midwall (natural)
strain:
The mathematical analysis for the evaluation of the
myocardial stiffness constants was carried out by an
interation procedure'101 using the non-linear curve-
fitting program1 '".
For the assessment of left ventricular relaxation
the time constant of left ventricular pressure decay
(7, in milliseconds) was calculated from the linear
regression between negative dP/dt and left
ventricular pressure after peak negative dP/dl up to
mitral valve opening:
where P=left ventricular pressure (mmHg) and
PB = pressure intercept at dP/d/ = 0*9l2).
For the assessment of left ventricular filling, peak
filling rate was determined in group 1 from left
ventricular cineangiograms. The mean filling rate
was calculated from the stroke volume divided by the
diastolic (mitral valve opening to end-diastole) filling
time interval. Left ventricular peak and mean
midwall lengthening rate were determined from the
digitized M-mode echocardiograms(9).
Results
ECHOCARDIOGRAPH1C FINDINGS (TABLE 1)
Septal wall thickness (>l-3 cm) and the ratio of
septal to posterior wall thickness (>l-3) were
increased in all patients. Left ventricular internal
diameter and systolic shortening were similar in both
groups. Systolic anterior motion (SAM) of the
anterior mitral leaflet was present in eight of nine
patients of group 1 and in five of six patients of
group 2.
STANDARD HAEMODYNAM1C MEASUREMENTS
(TABLE 2)
Heart rate decreased significantly from 85 to 69
beats/min following propranolol but remained
unchanged in group 2 after verapamil (71 vs. 74
beats/min). Left ventricular end-diastolic and peak
systolic pressure was unchanged after propranolol as
well as after verapamil. The systolic pressure gradient
decreased significantly from 22 to 12 mmHg follow-
ing propranolol but remained unchanged after
verapamil (28 vs. 30 mmHg). Left ventricular
maximum dP/dt decreased slightly although not
significantly in both groups after f} blockade and
verapamil. Left ventricular angiographic ejection
fraction decreased slightly from 82 to 77<7o in group
1, whereas left ventricular end-diastolic volume index
and systolic stroke volume remained unchanged after
propranolol. Ejection fraction and end-diastolic
volume in group 2 after administration of verapamil
were comparable to the angiographic data in group 1
after propranolol. However, control data in group 2
were not available according to our protocol. The
echocardiographic left ventricular end-diastolic
diameter increased slightly from 3-92 to 4-04 cm
after verapamil and systolic diameter shortening
decreased significantly from 35 to 30%.
DIASTOLIC FUNCTION PARAMETERS (TABLE 3)
The diastolic pressure-volume data showed no
significant change before and after propranolol (Fig.
3). The constant of left ventricular chamber stiffness
 A
(/?) and the intercept (a) decreased slightly although
not significantly after p blockade. The baseline
pressure (C) increased slightly after propranolol.
The diastolic stress-strain data in group 2 showed
no significant change in diastolic myocardial
function after administration of verapamil (Fig. 4).
The constant of left ventricular myocardial stiffness
(/}') and the intercept (a') remained unchanged
following verapamil. The constant of myocardial
viscosity (rf) and the reference midwall circumference
(/,) increased slightly although not significantly after
verapamil.
RELAXATION AND FILLING PARAMETERS (TABLE 4) *
Tincreased significantly from 45 to 66 ms in group
1 but decreased significantly from 53 to 43 ms in
group 2. The number of T values elapsed at the
lowest diastolic pressure (7"al p^, decreased slightly
after propranolol but increased slightly after
verapamil. The lowest diastolic pressure (P,J and t
peak negative dP/dt remained unchanged after both
propranolol and verapamil.
Left ventricular peak filling rate remained un-
changed in group 1 following propranolol, whereas
the mean filling rate significantly decreased. The
peak midwall lengthening rate in group 2 increased,
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Table t
Group
Group
f
1
2
Echocardiographic findings
HR
78
(60-94)
75
(50-94)
(3
(3
4-5
•7-5-
4-4
•6-5-
6)
6)
Sh
41
(35-38)
39
(32-47)
(1
(1
IVS
1-9
•3-2-
1-9
•4-2-
2)
2)
(0
(1
PW
1-1
• 9 - 1
1 1
•0-1
•2)
•2)
1VS/PW
(1
(1
1-8
•5-2-2)
1-7
•3-2-3)
HR, heart rate (beats/min); D^, left ventricular end-diastolic internal chamber diameter (cm); Sh, systolic shortening of
the internal diameter (%); IVS, septal wall thickness (cm); PW, posterior wall thickness (cm); IVS/PW, septal to posterior
wall ratio.
All data given are mean values and ranges'.
Table 2 Standard haemodynamics
HR LVEDP LVSP max dP/dt EF EDV1 SV1 D* Sh
Group 1
C,
Pr
Group 2
C2
V
85±7
69±5
71±4
74±7
21±3
24±3
17±4
17±2
144±10
137±10
152±10
146± 8
22±10
12± 7
28±13
30± 9
1842±121 82±3 90±6 73±5
1613±105 77±3 95±5 73±3
1597±129
1511±118 73±2 94±8 69±7
3-9±O-
4-0±0'
35±5
3O±4
C|, control run group 1; Pr, propranolol; C2, control run group 2; V, verapamil; HR, heart rate (beats/min); LVEDP,
left ventricular end-diastolic pressure (mmHg); LVSP, left ventricular peak systolic pressure (mmHg); AP, systolic pressure
gradient (mmHg); max dP/dt, maximal rate of left ventricular pressure rise (mmHg/s); EF, systolic ejection fraction (%);
EDV1, left ventricular volume index (ml/m2); SVI, stroke volume index (ml/m2); D^, left ventricular internal diameter at
end-diastole (cm); Sh, systolic shortening of the internal diameter (%); • P<0-05.
All data are given as mean values ±1 S.E.M
Table 3 Diastolic function data
(a) Pressure-volume relationship: Croup I
P
Pr
5-8±2-9
4-7±3-3
0-054±0-01
0-047±0-01
0-8±2-l
4-4±2-8
(b)
V
Stress-strain
4
5
relationship:
a'
•Odt l -8
•5±3-9
Group 2
P'
14-8±4-4
12-6±4-0
0-
2-
1
9±1-
8±0-
4
9
/,
13-8±1
14-1±1
•7
•5
a, intercept (mmHg); p, constant of chamber stiffness;
C, baseline pressure (mmHg); a', intercept (g/cm2); p',
constant of myocardial stiffness; rj, constant of myocardial
viscosity (g s cm"2); /,, left ventricular reference midwall
circumference at a common wall stress of 1 g/cm2 (cm); C,,
control run group 1; Pr, propranolol; C2, control run group
2; V, verapamil.
All data are given as mean values ±1 s EM
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however, from 3-7 to 5-5 cm/sec and mean midwall
lengthening rate increased significantly from 2-4 to
4-3 cm/sec following administration of verapamil.
Discussion
Improved relaxation and diastolic filling have been
reported in patients with hypertrophic cardio-
myopathy following administration of nifedipine(8).
A beneficial effect of 0 blocking agents on systolic
outflow gradient has been well established, whereas
the effect of p blocking agents on the passive diastolic
properties remains a matter of controversy'5'61.
Therefore, the purpose of the present study was to
examine the effect of propranolol and verapamil on
left ventricular diastolic mechanics in order to
determine whether or not left ventricular relaxation,
diastolic filling and passive diastolic chamber and
muscle properties are influenced by the administration
of these drugs. The study group included not only
patients with mild to moderate resting gradients but
i
E
LV volume (ml/m2)
Figure 3 Left ventricular pressure-volume
relationship in a patient before (open circles) and
after (closed circles) intravenous administration of
propranolol. Note that the diastolic pressure-
volume relationship remains unchanged after /3
blockade.
25
20
15
10
O Control
• Verapamil
O--O-'
0-10 0-20
Strain
Figure 4 Left ventricular viscoelastic stress - strain
relationship in a patient before (open circles) and after
(closed circles) intravenous administration of verapamil.
Note that the stress—strain relationship remains unchanged
before and after administration of verapamil.
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Table 4 Relaxation and filling data
(a) Croup I
c,
Pr
(b) Group 2
c2
V
T
45±S
66±11
T
53±7
43±9
Tu PL
3-6±0-6
3-3±O-5
7»l PL
4-2±0-7
4-9±0-8
PL
5-O±l-8
5-2±l-6
5-O±O-9
6-0±0-6
min dP/dt
1417±80
1248±99
min dP/dt
1379±117
1346±98
/ P
607±125
736±I27
'P
3-7±O-9
5 - 5 ± l l
fn,
256±32
196±29
lm
2-4±0-7
4-3±O-8 *•
T, time constant of left ventricular pressure decay (ms); 7"al p., rvalues elapsed at the lowest diastolic pressure; PL ,
lowest diastolic pressure (mmHg); min dP/dt, maximal rate of left ventricular pressure fall (mmHg/s)^, , left ventricular
peak filling rate (ml m~2 s - ' ) ; / m . left ventricular mean filling rate (ml m~2 s-1); /p, left ventricular peak midwall
lengthening rate (cm/s); /m, left ventricular mean midwall lengthening rate (cm/s); *P<0-05; **P<0-025; C,, control run
group 1; Pr, propranolol; C2, control run group 2; V, verapamil.
All data are given as mean values±l S.E.M.
also four patients with provocable systolic pressure
gradients in group 1 and three patients with minimal
resting outflow gradients (<10 mmHg) in gToup 2.
Therefore, our results are valid for patients with no or
moderate pressure gradients, and might not be
extrapolated to patients with large outflow tract
gradients who are operated on at our institution.
The data suggest that left ventricular relaxation is
delayed in patients with hypertrophic
cardiomyopathy following 0 blockade probably due
to negative inotropic effect of propranolol and due
to the change in heart rate(l2). In contrast, left
ventricular relaxation is enhanced after adminis-
tration of verapamil, probably due to a direct effect
of the calcium channel blocker on the deactivation
process in patients with hypertrophic cardio-
myopathy. Since loading conditions were not
significantly altered after verapamil, the changes in
left ventricular relaxation cannot be explained by
unloading of the left ventricle. Usually, 3 to 5 min
-S -500
I
E
- -1000
•o
TJ
1
 -1500
-2000
\
\o \
\ * \
\ ' \
\
25 50 75 100
LVP (mmHg)
25 50 75 100
Figure 5 Left ventricular negative dP/dt vs. pressure plot in a patient with
hypertrophic cardiomyopathy before and after propranolol (left hand panel) as
well as before and after verapamil (right hand panel). The control data are
represented by the open symbols and the propranolol and the verapamil data by the
closed symbols. Note that the time constant of left ventricular pressure decay (77) is
increased from 53 to 76 ms after propranolol but is decreased from 57 to 43 ms after
verapamil. LVP, left ventricular pressure; -dP/dt, negative dP/dt.
54 O.M.Hessetal.
after infusion of verapamil, there was an increase in
heart rate and a decrease in aortic pressure due to
peripheral vasodilatation. However, our
measurements were performed 10 to 15 min after
infusion of verapamil, when heart rate and aortic
pressure were back to control (Table 1). The mild
negative inotropic effect of verapamil with a decrease
in systolic shortening of the left ventricular internal
diameter would tend to decrease the rate of
relaxation rather than to increase it. Thus, verapamil
is associated with an improvement in left ventricular
relaxation, and, therefore, facilitates diastolic filling
by lowering early diastolic filling pressures.
Therefore, one would expect an improved diastolic
filling rate after administration of verapamil but a
decreased filling rate after propranolol. Our data
confirm that diastolic filling is improved after
verapamil but is impaired after propranolol with a
decrease in mean diastolic filling rate. The analysis of
diastolic chamber and muscle stiffness, however,
showed no change in left ventricular diastolic passive
properties after the administration verapamil or
propranolol.
Thus, we can conclude that the beneficial effect of
verapamil on diastolic mechanics is related to
improved relaxation and diastolic filling rather than
to changes in myocardial wall stiffness. In contrast,
the beneficial effect of propranolol appears to be
related to the reduction of systolic outflow gradient
rather than to changes in diastolic filling or passive
chamber stiffness. This might explain the lack of
clinical improvement in some patients with hyper-
trophic cardiomyopathy treated with propranolol,
especially those without outflow obstruction.
The work reported in this paper was supported by the
Swiss National Science Foundation.
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Kaltenbach In some respects your findings are in
agreement with ours, but in others there is
disagreement. This disagreement concerns systolic
function after verapamil. If I am correct you have
found a change towards improved diastolic function
but no essential change in systolic function. We have
found both improved diastolic function and reduced
contractility. I assume the reason for this difference
is the method of administering verapamil. If you
compare a bolus of propranolol with a bolus of
verapamil there are significant differences. 1 think a
bolus injection of verapamil can only be evaluated if
sympathetic activity is blocked or if the substance is
given as a prolonged infusion or by oral adminis-
tration. But if bolus administration of verapamil is
evaluated, then the effect of the calcium blocker and '
the effect of increased sympathetic activity are
superimposed.
Hess We did not want to blunt our results by
administration of /3-blocking agents before
verapamil. It was actually not a bolus injection that
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we used but rather an intravenous infusion for about
3 to 4 min. It was very interesting to see that after
2 or 3 min of verapamil administration, we had, first,
an increase in most patients' pressure gradient. The
measurements which we have presented here were
made 10 to 15 min after administration of the drug,
when the haemodynamic situation was almost back to
the control level. You have seen that the heart rate was
not significantly different before and after
administration of verapamil.
Kaltenbach It was an increase from 71 to 74
beats/min, this might not be a significant#difference,
but . . .
Hess It was more, you know, when you look at the
5 min values after administration of verapamil;
we had an increase from about 70 to 80 and then it
came back 10 min after to the values which we had
had before. Although the pressure gradient was
unchanged after 10 min, 5 min after administration
we saw in most patients an increase in outflow
gradient.
And now to your other question. We have seen in
some patients a decrease in contractility. We have
studied six patients with verapamil only and we have
seen a slight decrease in dP/dtmlLK. And the ejection
fraction was also lower, 73% after verapamil as
compared to 82% in group 1 at rest. I think we had a
mild effect on systolic function.
Bertrand I have two questions. Have you studied
the effects of other calcium antagonists, especially
nifedipine, in these particular patients? My second
question is: Obviously, when you are injecting
verapamil intravenously, you have direct myocardial
effects and also peripheral effects. Have you studied
the direct myocardial effect by injecting the drug
directly into the left coronary artery, in order to
separate the two effects of the drug?
Hess To answer the second question first, we did
not inject it directly because you know that you get
asynchronous contractions when you inject directly in
the coronary artery and you may not be sure what you
are going to find; you probably see a decrease in
everything because you have left ventricular
asynchrony.
Now to your first question. In a non-invasive study,
we evaluated the effects of nifedipine on relaxation.
We have seen an increase in peak lengthening rate and
found that filling was improved after the
administration of nifedipine similar to our present
study.
Schmiel I would like to make some remarks and put
some questions concerning the method you used.
First, there exists one paper by Rutishauser from the
late 1960s in which he demonstrated that the
pressure fall during the relaxation period, during the
isovolumic relaxation period, was not constant. That
means, the ratio of dP/dT divided by the
instantaneous pressure does not remain constant and
that means the description by a function as Weiss used
it is not adequate. You must use a modified
exponential function to do this. The second thing is,
how did you determine your strain from the
dimensional data? I think it is practically impossible
to determine the resting length of the heart muscle.
The third point is a remark concerning these
parameters that you determined by a non-linear
fitting. Our experience is that if you analyse two or
three consecutive heart beats, the parameters are
significantly different from what you achieve by this
analysis.
Hess We are well aware that the downslope might
not be linear for the dP/dt vs. P regression. As Dr
Murgo pointed out, there might be a biphasic slope
and there might be some other problem with this
kind of analysis. However, you all know that after
propranolol with a decrease in contractility there must
be a decrease in the rate of relaxation. With verapamil
you can see an increase in relaxation rate, as it was
shown in the paper of Lorell and coworkers. The way
in which we do our analysis might be wrong. Maybe in
patients with hypertrophic cardiomyopathy and
asymmetric hypertrophy we should better use a
regional relaxation parameter. I do not know an
answer, but this is probably the best way as we did it.
Now to the second point, we had a publication some
years ago where we showed that you can't get zero
pressure in patients because you can't do caval
occlusion and bring the lowest pressure down to zero.
Thus, we use an extrapolation procedure; here we do
first a fit to the pressure-circumferential wall length
relation and determine the circumferential length at
the calculated stress of 1 g/cm2 or the calculated
volume of 1 mmHg. This length is used for
normalization. This is an assumption, probably the
best one, to get normalized data in patients.
Now to the third point, to the analysis of
consecutive beats. Our data showed that there was no
change before and after propranolol and before and
after verapamil. This shows that the model used was
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probably okay, because we could not see any
difference between the patients. If you see a
difference from beat to beat, then you must have
used the wrong model, I should say.
Schmiel You demonstrated only the plots, but not
the parameter of the curves, and the plots seem to be
identical, but I believe that the parameters of the
curves are significantly different.
Hess No, they were exactly the same; the single
parameters were on the top of the figure. You could
see that the stiffness data were the same.
Frank We have found that the time to maximum
improvement clinically is often as much as 2 years
from the beginning of the administration of
propranolol. Do you have any data with repeated
invasive studies, assuming that the method of
measurement is at least satisfactory from the point of
view using the patient as his own control?
Hess No. Professor Rothlin will show some data of a
clinical follow-up study of patients with propranolol
and verapamil. These patients showed a lower
mortality rate than untreated patients. We did not
repeat our measurements, otherwise you would have
to recatheterize the patients. 1 am not sure if you would
find different results.
